ArticleJournal of inflammation research2026
Bioinformatic Analysis and Experimental Verification Reveal the Protective Role of Baicalein Against LPS-Induced Endothelial Cell Dysfunction.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endothelial cells play a central role in the pathogenesis of sepsis. Currently, effective therapeutic options for sepsis remain limited. Baicalein (BAI) is a compound with multiple bioactivities. This study aims to investigate the protective effects of BAI against lipopolysaccharide (LPS)-induced endothelial cell injury and to explore the underlying molecular mechanisms. Methods: Bioinformatics tools, including RNA sequencing (RNA-seq), immune cell infiltration analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, were utilized to explore the molecular mechanisms of BAI in human umbilical vein endothelial cells (HUVECs) induced by LPS. The LPS-induced HUVECs model was used to assess the effects of BAI through CCK8 assays, cell permeability assays, and RT-qPCR. Results: RNA-seq analysis revealed a set of differentially expressed genes (DEGs) shared between the Control group vs LPS group and LPS vs Baicalein group, including vascular cell adhesion molecule 1 (VCAM1), phosphoinositide-specific phospholipase C X-domain containing 1 (PLCXD1), and MIR3142 host gene (MIR3142HG), a long non-coding RNA. GO, KEGG, and Reactome enrichment analyses indicated that the DEGs were primarily enriched in TNF signaling, NF-κB signaling, and immune regulation pathways. Molecular docking and molecular dynamics simulation analyses revealed that BAI exhibits a strong binding affinity for key targets VCAM1 and PLCXD1. ROC analysis revealed that these core genes, VCAM1 and PLCXD1, exhibited significant diagnostic potential for sepsis. The cell experimental results demonstrated that BAI significantly alleviated the expression levels of inflammatory markers (such as IL-6 and IL-1β) and reduced endothelial cell permeability induced by LPS in HUVECs. Conclusion: BAI may alleviate LPS-induced endothelial cell injury by modulating the inflammatory response and immune microenvironment through the regulation of MIR3142HG, VCAM1, and PLCXD1 targets. This study provides new molecular targets and theoretical insights for sepsis therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.